Table 2.

The efficacy and safety of biological and biosimilar treatment of RA compared to placebo, the results of the mixed treatment comparison

Treatment	ACR20 at week 24 OR [95 % CI]	ACR50 at week 24 OR [95 % CI]	Serious AEs OR [95 % CI]
Abatacept vs placebo	3.7 [2.17–6.06]	3.64 [2.25–5.76]	0.91 [0.64–1.18]
Adalimumab vs placebo	2.92 [1.9–4.36]	3.48 [2.27–5.22]	0.85 [0.57–1.19]
Certolizumab pegol vs placebo	7.69 [3.69–14.26]	8.46 [3.74–16.82]	2.02 [1.16–3.3]
Etanercept vs placebo	2.72 [1.47–4.71]	3.07 [1.68–5.38]	0.84 [0.48–1.34]
Golimumab vs placebo	2.8 [1.5–4.83]	2.83 [1.48–4.98]	1.63 [0.74–3.14]
Infliximab vs placebo	2.71 [1.51–4.54]	3.3 [1.82–5.66]	1.15 [0.77–1.64]
Rituximab vs placebo	2.81 [1.5–4.86]	3.19 [1.66–5.62]	1.18 [0.7–1.87]
Tocilizumab vs placebo	3.69 [1.87–6.62]	5.57 [2.77–10.09]	1.46 [0.89–2.27]
Infliximab-biosimilar vs placebo	3.47 [0.85–9.7]	4.06 [1.01–11.54]	1.87 [0.74–3.84]